Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis
BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis
BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis
Submitted by
admin
on January 12, 2024 - 9:40am
Source:
BioSpace
News Tags:
Bioinvent
Exelixis
immuno-oncology
Headline:
BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis
snippet:
Full rights returned following Exelixis' corporate restructuring announced January 07, 2024
Collaboration generated novel targets and antibodies for use in immuno-oncology therapeutics
Do Not Allow Advertisers to Use My Personal information
